The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer

Cancer Letters

Volumn 352, Issue 1, 2014, Pages 36-53

  Weitzenfeld, Polina ^a   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; CCR5 CCL5; CXCR4 CXCL12; Maraviroc; Personalized therapy; Plerixafor

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ANTINEOPLASTIC AGENT; BL 8040; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CTCE 9908; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; DALTEPARIN; ENOXAPARIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MARAVIROC; MSX 122; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; OTR 4120; OTR 4131; PLERIXAFOR; POL 6326; RANTES; STROMAL CELL DERIVED FACTOR 1; TINZAPARIN; TN 14003; ULOCUPLUMAB; UNCLASSIFIED DRUG; VICRIVIROC; XAPARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SIZE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON CARCINOMA; COLORECTAL CANCER; CYTOKINE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; METASTASIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; SHORT SURVEY; STOMACH CANCER; SURVIVAL TIME; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

CANCER; CCR5-CCL5; CXCR4-CXCL12; MARAVIROC; PERSONALIZED THERAPY; PLERIXAFOR;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 84906047226     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.006     Document Type: Review

References (239)

1. Sallusto F., Baggiolini M. Chemokines and leukocyte traffic. Nat. Immunol. 2008, 9:949-952.
2. A.B.-B.F. Bachelerie, A.M. Burkhardt, C.Combadiere, J.M. Farber, G.J. Graham, R. Horuk, A.H. Sparre-Ulrich, M. Locati, A.D. Luster, A. Mantovani, K. Matsushima, P.M. Murphy, R. Nibbs, H. Nomiyama, C.A. Power, A.E. I. Proudfoot, M.M. Rosenkilde, A. Rot, S. Sozzani, M. Thelen, O. Yoshie, A. Zlotnik, Update on the extended family of chemokine receptors, Pharmacological Reviews (in press).
3. Zlotnik A., Yoshie O., Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 2006, 7:243.
4. Mantovani A., Bonecchi R., Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat. Rev. Immunol. 2006, 6:907-918.
5. Balkwill F.R. The chemokine system and cancer. J. Pathol. 2012, 226:148-157.
6. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
7. Middleton J., Patterson A.M., Gardner L., Schmutz C., Ashton B.A. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002, 100:3853-3860.
8. White G.E., Iqbal A.J., Greaves D.R. CC chemokine receptors and chronic inflammation-therapeutic opportunities and pharmacological challenges. Pharmacol. Rev. 2013, 65:47-89.
9. Shachar I., Karin N. The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J. Leukocyte Biol. 2013, 93:51-61.
10. Hughes A., Nelson M. HIV entry: new insights and implications for patient management. Curr. Opin. Infect Dis. 2009, 22:35-42.
11. Coakley E., Petropoulos C.J., Whitcomb J.M. Assessing chemokine co-receptor usage in HIV. Curr. Opin. Infect Dis. 2005, 18:9-15.
12. Kitaya K., Yamada H. Pathophysiological roles of chemokines in human reproduction: an overview. Am. J. Reprod. Immunol. 2011, 65:449-459.
13. Mithal D.S., Banisadr G., Miller R.J. CXCL12 signaling in the development of the nervous system. J. Neuroimmune Pharmacol. 2012, 7:820-834.
14. Yadav A., Saini V., Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin. Chim. Acta 2010, 411:1570-1579.
15. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
16. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
17. Ruffell B., DeNardo D.G., Affara N.I., Coussens L.M. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010, 21:3-10.
18. Shiao S.L., Ganesan A.P., Rugo H.S., Coussens L.M. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011, 25:2559-2572.
19. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
20. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
21. Balkwill F., Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther. 2010, 87:401-406.
22. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
23. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
24. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat. Rev. Cancer 2009, 9:57-63.
25. Tan T.T., Coussens L.M. Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 2007, 19:209-216.
26. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., Wang J.M. Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol. 2007, 7:1271-1285.
27. Sica A., Porta C., Morlacchi S., Banfi S., Strauss L., Rimoldi M., Totaro M.G., Riboldi E. Origin and functions of tumor-associated myeloid cells (TAMCs). Cancer Microenviron. 2012, 5:133-149.
28. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122:787-795.
29. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
30. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
31. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 2010, 59:1593-1600.
32. Gerald D., Chintharlapalli S., Augustin H.G., Benjamin L.E. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013, 73:1649-1657.
33. Fridlender Z.G., Albelda S.M. Tumor-associated neutrophils: friend or foe?. Carcinogenesis 2012, 33:949-955.
34. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., Worthen G.S., Albelda S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
35. Granot Z., Henke E., Comen E.A., King T.A., Norton L., Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011, 20:300-314.
36. Leibovich-Rivkin T., Lebel-Haziv Y., Lerrer S., Weitzenfeld P., Ben-Baruch A. The versatile world of inflammatory chemokines in cancer. The Tumor Immunoenvironment 2013, 135-175. Springer, Netherlands. M.R. Shurin, V. Umansky, A. Malyguine (Eds.).
37. Mantovani A., Savino B., Locati M., Zammataro L., Allavena P., Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010, 21:27-39.
38. Fulton A.M. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr. Oncol. Rep. 2009, 11:125-131.
39. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008, 267:271-285.
40. Lazennec G., Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 2010, 16:133-144.
41. Franciszkiewicz K., Boissonnas A., Boutet M., Combadiere C., Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res. 2012, 72:6325-6332.
42. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G.M., Feng Z.H. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007, 252:86-92.
43. Keeley E.C., Mehrad B., Strieter R.M. CXC chemokines in cancer angiogenesis and metastases. Adv. Cancer Res. 2010, 106:91-111.
44. Fujita M., Zhu X., Ueda R., Sasaki K., Kohanbash G., Kastenhuber E.R., McDonald H.A., Gibson G.A., Watkins S.C., Muthuswamy R., Kalinski P., Okada H. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res. 2009, 69:1587-1595.
45. Ben-Baruch A. Expert commentary: The chemokine receptor CXCR3 and its ligands in malignancy: do they act as double-edged swords?. Chemokine Research Trend 2008, 1-6. Springer Publishers.
46. Keeley E.C., Mehrad B., Strieter R.M. Chemokines as mediators of neovascularization. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1928-1936.
47. Gonzalez-Martin A., Mira E., Manes S. CCR5 as a potential target in cancer therapy: inhibition or stimulation?. Anticancer Agents Med. Chem. 2012, 12:1045-1057.
48. Gonzalez-Martin A., Gomez L., Lustgarten J., Mira E., Manes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res. 2011, 71:5455-5466.
49. Lapteva N., Huang X.F. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin. Biol. Ther. 2010, 10:725-733.
50. Robinson S.C., Scott K.A., Wilson J.L., Thompson R.G., Proudfoot A.E., Balkwill F.R. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 2003, 63:8360-8365.
51. Soria G., Ben-Baruch A. The CCL5/CCR5 Axis in Cancer 2009, Humana Press. first ed.
52. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
53. Gu-Trantien C., Loi S., Garaud S., Equeter C., Libin M., de Wind A., Ravoet M., Le Buanec H., Sibille C., Manfouo-Foutsop G., Veys I., Haibe-Kains B., Singhal S.K., Michiels S., Rothe F., Salgado R., Duvillier H., Ignatiadis M., Desmedt C., Bron D., Larsimont D., Piccart M., Sotiriou C., Willard-Gallo K. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 2013, 123:2873-2892.
54. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008, 66:1-9.
55. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
56. Lee H.W., Choi H.J., Ha S.J., Lee K.T., Kwon Y.G. Recruitment of monocytes/macrophages in different tumor microenvironments. Bba-Rev. Cancer 1835, 2013:170-179.
57. Lee H.W., Choi H.J., Ha S.J., Lee K.T., Kwon Y.G. Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim. Biophys. Acta 1835, 2012:170-179.
58. Lu X., Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J. Biol. Chem. 2009, 284:29087-29096.
59. Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature 2013, 496:445-455.
60. Conti I., Rollins B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 2004, 14:149-154.
61. Keeley E.C., Mehrad B., Strieter R.M. Chemokines as mediators of tumor angiogenesis and neovascularization. Exp. Cell Res. 2011, 317:685-690.
62. Huang J., Chen K., Gong W., Dunlop N.M., Wang J.M. G-protein coupled chemoattractant receptors and cancer. Front. Biosci. 2008, 13:3352-3363.
63. Darash-Yahana M., Pikarsky E., Abramovitch R., Zeira E., Pal B., Karplus R., Beider K., Avniel S., Kasem S., Galun E., Peled A. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004, 18:1240-1242.
64. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
65. Ping Y.F., Yao X.H., Jiang J.Y., Zhao L.T., Yu S.C., Jiang T., Lin M.C.M., Chen J.H., Wang B., Zhang R., Cui Y.H., Qian C., Wang J.M., Bian X.W. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J. Pathol. 2011, 224:344-354.
66. Liekens S., Schols D., Hatse S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr. Pharm. Des. 2012, 16:3903-3920.
67. Ping Y.F., Yao X.H., Jiang J.Y., Zhao L.T., Yu S.C., Jiang T., Lin M.C., Chen J.H., Wang B., Zhang R., Cui Y.H., Qian C., Wang J., Bian X.W. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J. Pathol. 2011, 224:344-354.
68. Mishra P., Banerjee D., Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J. Leukoc. Biol. 2011, 89:31-39.
69. Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., Onder T.T., Wang Z.C., Richardson A.L., Weinberg R.A., Orimo A. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA 2010, 107:20009-20014.
70. Zlotnik A., Burkhardt A.M., Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat. Rev. Immunol. 2011, 11:597-606.
71. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 2010, 16:2927-2931.
72. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin. Exp. Metastasis 2008, 25:345-356.
73. Ben-Baruch A. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion. Cell Adhes. Migr. 2009, 3:328-333.
74. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
75. Fernando R.I., Castillo M.D., Litzinger M., Hamilton D.H., Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011, 71:5296-5306.
76. Palena C., Hamilton D.H., Fernando R.I. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 2012, 8:713-722.
77. Kim M., Koh Y.J., Kim K.E., Koh B.I., Nam D.H., Alitalo K., Kim I., Koh G.Y. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res. 2010, 70:10411-10421.
78. Castellana D., Zobairi F., Martinez M.C., Panaro M.A., Mitolo V., Freyssinet J.M., Kunzelmann C. Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res. 2009, 69:785-793.
79. Granot Z., Henke E., Comen E.A., King T.A., Norton L., Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011, 20:300-314.
80. Richmond A., Yang J., Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res. 2009, 22:175-186.
81. Amiri K.I., Richmond A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev. 2005, 24:301-313.
82. Acosta J.C., Gil J. A role for CXCR2 in senescence, but what about in cancer?. Cancer Res. 2009, 69:2167-2170.
83. Orjalo A.V., Bhaumik D., Gengler B.K., Scott G.K., Campisi J. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl. Acad. Sci. USA 2009, 106:17031-17036.
84. Fujita M., Zhu X.M., Ueda R., Sasaki K., Kohanbash G., Kastenhuber E.R., McDonald H.A., Gibson G.A., Watkins S.C., Muthuswamy R., Kalinski P., Okada H. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res. 2009, 69:1587-1595.
85. Liu C., Luo D.F., Reynolds B.A., Meher G., Katritzky A.R., Lu B., Gerard C.J., Bhadha C.P., Harrison J.K. Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis 2011, 32:129-137.
86. Ma X.R., Norsworthy K., Kundu N., Rodgers W.H., Gimotty P.A., Goloubeva O., Lipsky M., Li Y., Holt D., Fulton A. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol. Cancer Ther. 2009, 8:490-498.
87. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
88. Levy J.A. The unexpected pleiotropic activities of RANTES. J. Immunol. 2009, 182:3945-3946.
89. Nesbeth Y.C., Martinez D.G., Toraya S., Scarlett U.K., Cubillos-Ruiz J.R., Rutkowski M.R., Conejo-Garcia J.R. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J. Immunol. 2010, 184:5654-5662.
90. Inoue H., Iga M., Xin M., Asahi S., Nakamura T., Kurita R., Nakayama M., Nakazaki Y., Takayama K., Nakanishi Y., Tani K. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol. Immunother. 2008, 57:1399-1411.
91. Chang L.-Y., Lin Y.-C., Mahalingam J., Huang C.-T., Chen T.-W., Kang C.-W., Peng H.-M., Chu Y.-Y., Chiang J.-M., Dutta A., Day Y.-J., Chen T.-C., Yeh C.-T., Lin C.-Y. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 2012, 72:1092-1102.
92. Borczuk A.C., Papanikolaou N., Toonkel R.L., Sole M., Gorenstein L.A., Ginsburg M.E., Sonett J.R., Friedman R.A., Powell C.A. Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene 2008, 27:557-564.
93. Soria G., Ofri-Shahak M., Haas I., Yaal-Hahoshen N., Leider-Trejo L., Leibovich-Rivkin T., Weitzenfeld P., Meshel T., Shabtai E., Gutman M., Ben-Baruch A. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011, 11:130.
94. Luboshits G., Shina S., Kaplan O., Engelberg S., Nass D., Lifshitz-Mercer B., Chaitchik S., Keydar I., Ben-Baruch A. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999, 59:4681-4687.
95. Soria G., Yaal-Hahoshen N., Azenshtein E., Shina S., Leider-Trejo L., Ryvo L., Cohen-Hillel E., Shtabsky A., Ehrlich M., Meshel T., Keydar I., Ben-Baruch A. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 2008, 44:191-200.
96. Yaal-Hahoshen N., Shina S., Leider-Trejo L., Barnea I., Shabtai E.L., Azenshtein E., Greenberg I., Keydar I., Ben-Baruch A. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin. Cancer Res. 2006, 12:4474-4480.
97. Sugasawa H., Ichikura T., Kinoshita M., Ono S., Majima T., Tsujimoto H., Chochi K., Hiroi S., Takayama E., Saitoh D., Seki S., Mochizuki H. Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int. J. Cancer 2008, 122:2535-2541.
98. Laubli H., Spanaus K.-S., Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 2009, 114:4583-4591.
99. Mi Z., Bhattacharya S.D., Kim V.M., Guo H., Talbot L.J., Kuo P.C. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011, 32:477-487.
100. Su X., Ye J., Hsueh E.C., Zhang Y., Hoft D.F., Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 2010, 184:1630-1641.
101. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
102. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell. Signal. 2004, 16:1201-1210.
103. Wang S.-W., Wu H.-H., Liu S.-C., Wang P.-C., Ou W.-C., Chou W.-Y., Shen Y.-S., Tang C.-H. CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS ONE 2012, 7:e35101.
104. Aldridge V., Garg A., Davies N., Bartlett D.C., Youster J., Beard H., Kavanagh D.P., Kalia N., Frampton J., Lalor P.F., Newsome P.N. Human mesenchymal stem cells are recruited to injured liver in a beta1-integrin and CD44 dependent manner. Hepatology 2012, 56:1063-1073.
105. Spring H., Schuler T., Arnold B., Hammerling G.J., Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl. Acad. Sci. USA 2005, 102:18111-18116.
106. Ishida Y., Kimura A., Kuninaka Y., Inui M., Matsushima K., Mukaida N., Kondo T. Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing. J. Clin. Invest. 2012, 122:711-721.
107. Zhang Y., Yao F., Yao X., Yi C., Tan C., Wei L., Sun S. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol. Rep. 2009, 21:1113-1121.
108. Niwa Y., Akamatsu H., Niwa H., Sumi H., Ozaki Y., Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin. Cancer Res. 2001, 7:285-289.
109. Hartmann M.C., Dwyer R.M., Costello M., Potter S.M., Curran C., Hennessy E., Newell J., Griffin D.G., Kerin M.J. Relationship between CCL5 and transforming growth factor-beta1 (TGFbeta1) in breast cancer. Eur. J. Cancer 2011, 47:1669-1675.
110. Lin S., Wan S., Sun L., Hu J., Fang D., Zhao R., Yuan S., Zhang L. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci. 2012, 103:904-912.
111. Wu F.-Y., Ou Z.-L., Feng L.-Y., Luo J.-M., Wang L.-P., Shen Z.-Z., Shao Z.-M. Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol. Cancer Res. 2008, 6:1276-1288.
112. Chang L.-Y., Lin Y.-C., Kang C.-W., Hsu C.-Y., Chu Y.-Y., Huang C.-T., Day Y.-J., Chen T.-C., Yeh C.-T., Lin C.-Y. The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. J. Immunol. (Baltimore, Md: 1950) 2012, 189:567-574.
113. Tan M.C., Goedegebuure P.S., Belt B.A., Flaherty B., Sankpal N., Gillanders W.E., Eberlein T.J., Hsieh C.S., Linehan D.C. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 2009, 182:1746-1755.
114. Zhang Y., Lv D., Kim H.J., Kurt R.A., Bu W., Li Y., Ma X. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res. 2013, 23:394-408.
115. Suffee N., Richard B., Hlawaty H., Oudar O., Charnaux N., Sutton A. Angiogenic properties of the chemokine RANTES/CCL5. Biochem. Soc. Trans. 2011, 39:1649-1653.
116. Suffee N., Hlawaty H., Meddahi-Pelle A., Maillard L., Louedec L., Haddad O., Martin L., Laguillier C., Richard B., Oudar O., Letourneur D., Charnaux N., Sutton A. RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans. Angiogenesis 2012, 15:727-744.
117. Wu Y., Li Y.Y., Matsushima K., Baba T., Mukaida N. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J. Immunol. 2008, 181:6384-6393.
118. Cambien B., Richard-Fiardo P., Karimdjee B.F., Martini V., Ferrua B., Pitard B., Schmid-Antomarchi H., Schmid-Alliana A. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS ONE 2011, 6:e28842.
119. Vaday G.G., Peehl D.M., Kadam P.A., Lawrence D.M. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006, 66:124-134.
120. Murooka T.T., Rahbar R., Fish E.N. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem. Biophys. Res. Commun. 2009, 387:381-386.
121. Gallo M., De Luca A., Lamura L., Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann. Oncol. 2012, 23:597-604.
122. Long H., Xie R., Xiang T., Zhao Z., Lin S., Liang Z., Chen Z., Zhu B. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells 2012, 30:2309-2319.
123. Velasco-Velazquez M., Jiao X., De La Fuente M., Pestell T.G., Ertel A., Lisanti M.P., Pestell R.G. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012, 72:3839-3850.
124. Velasco-Velazquez M., Jiao X., De La Fuente M., Pestell T.G., Ertel A., Lisanti M.P., Pestell R.G. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012, 72:3839-3850.
125. Chang L.Y., Lin Y.C., Mahalingam J., Huang C.T., Chen T.W., Kang C.W., Peng H.M., Chu Y.Y., Chiang J.M., Dutta A., Day Y.J., Chen T.C., Yeh C.T., Lin C.Y. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 2012, 72:1092-1102.
126. Laubli H., Spanaus K.S., Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 2009, 114:4583-4591.
127. Adler E.P., Lemken C.A., Katchen N.S., Kurt R.A. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol. Lett. 2003, 90:187-194.
128. Chang L.Y., Lin Y.C., Kang C.W., Hsu C.Y., Chu Y.Y., Huang C.T., Day Y.J., Chen T.C., Yeh C.T., Lin C.Y. The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. J. Immunol. 2012, 189:567-574.
129. Song J.K., Park M.H., Choi D.Y., Yoo H.S., Han S.B., Yoon do Y., Hong J.T. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and upregulation of IL-1Ra in melanoma model. PLoS ONE 2012, 7:e33747.
130. Wang S.W., Wu H.H., Liu S.C., Wang P.C., Ou W.C., Chou W.Y., Shen Y.S., Tang C.H. CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS ONE 2012, 7:e35101.
131. Yu L., Cecil J., Peng S.B., Schrementi J., Kovacevic S., Paul D., Su E.W., Wang J. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene 2006, 374:174-179.
132. Janowski M. Functional diversity of SDF-1 splicing variants. Cell Adhes. Migr. 2009, 3:243-249.
133. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., Dewor M., Georgiev I., Schober A., Leng L., Kooistra T., Fingerle-Rowson G., Ghezzi P., Kleemann R., McColl S.R., Bucala R., Hickey M.J., Weber C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 2007, 13:587-596.
134. Schiraldi M., Raucci A., Munoz L.M., Livoti E., Celona B., Venereau E., Apuzzo T., De Marchis F., Pedotti M., Bachi A., Thelen M., Varani L., Mellado M., Proudfoot A., Bianchi M.E., Uguccioni M. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 2012, 209:551-563.
135. Saini V., Staren D.M., Ziarek J.J., Nashaat Z.N., Campbell E.M., Volkman B.F., Marchese A., Majetschak M. The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1alpha function through distinct receptor interactions. J. Biol. Chem. 2011, 286:33466-33477.
136. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z.H., Penfold M.E.T., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C., Schall T.J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203:2201-2213.
137. Nair S., Schilling T.F. Chemokine signaling controls endodermal migration during zebrafish gastrulation. Science 2008, 322:89-92.
138. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
139. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., Kitamura Y., Matsushima K., Yoshida N., Nishikawa S., Kishimoto T., Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393:591-594.
140. Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., Yoshida N., Kikutani H., Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382:635-638.
141. Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., Bronson R.T., Springer T.A. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. USA 1998, 95:9448-9453.
142. Sharma M., Afrin F., Satija N., Tripathi R.P., Gangenahalli G.U. Stromal-derived factor-1/CXCR4 signaling: indispensable role in homing and engraftment of hematopoietic stem cells in bone marrow. Stem Cells Dev. 2011, 20:933-946.
143. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., Aiuti A., Springer T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 1996, 184:1101-1109.
144. Hori T., Sakaida H., Sato A., Nakajima T., Shida H., Yoshie O., Uchiyama T. Detection and delineation of CXCR-4 (Fusin) as an entry and fusion cofactor for T cell-tropic HIV-1 by three different monoclonal antibodies. J. Immunol. 1998, 160:180-188.
145. Gupta S.K., Lysko P.G., Pillarisetti K., Ohlstein E., Stadel J.M. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J. Biol. Chem. 1998, 273:4282-4287.
146. Murdoch C., Monk P.N., Finn A. Functional expression of chemokine receptor CXCR4 on human epithelial cells. Immunology 1999, 98:36-41.
147. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
148. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 2004, 14:171-179.
149. Micke P., Ostman A. Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin. Ther. Targets 2005, 9:1217-1233.
150. Domanska U.M., Kruizinga R.C., Nagengast W.B., Timmer-Bosscha H., Huls G., de Vries E.G.E., Walenkamp A.M.E. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur. J. Cancer 2013, 49:219-230.
151. Sun X.Q., Cheng G.C., Hao M.G., Zheng J.H., Zhou X.M., Zhang J.A., Taichman R.S., Pienta K.J., Wang J.H. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metast. Rev. 2010, 29:709-722.
152. Ben-Baruch A. Site-specific metastasis formation Chemokines as regulators of tumor cell adhesion, motility and invasion. Cell Adhes. Migr. 2009, 3:328-333.
153. Mukherjee D., Zhao J. The role of chemokine receptor CXCR4 in breast cancer metastasis. Am. J. Cancer Res. 2013, 3:46-57.
154. Hawkins O.E., Richmond A. The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res. 2012, 14:103.
155. Geminder H., Sagi-Assif O., Goldberg L., Meshel T., Rechavi G., Witz I.P., Ben-Baruch A. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol. 2001, 167:4747-4757.
156. Jankowski K., Kucia M., Wysoczynski M., Reca R., Zhao D.L., Trzyna E., Trent J., Peiper S., Zembala M., Ratajczak J., Houghton P., Janowska-Wieczorek A., Ratajczak M.Z. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003, 63:7926-7935.
157. Bartolome R.A., Ferreiro S., Miquilena-Colina M.E., Martinez-Prats L., Soto-Montenegro M.L., Garcia-Bernal D., Vaquero J.J., Agami R., Delgado R., Desco M., Sanchez-Mateos P., Teixido J. The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am. J. Pathol. 2009, 174:602-612.
158. Arya M., Tatoud R., McGurk C., O'Donoghue N., Klocker H., Williamson M., Masters J.R. The importance of the CXCL12: CXCR4 chemokine ligand: receptor interaction in prostate cancer metastasis. J. Urol. 2003, 169:291-303.
159. Phillips R.J., Burdick M.D., Lutz M., Belperio J.A., Keane M.P., Strieter R.M. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Resp. Crit. Care 2003, 167:1676-1686.
160. Arya M., Patel H.R., McGurk C., Tatoud R., Klocker H., Masters J., Williamson M. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J. Exp. Ther. Oncol. 2004, 4:291-303.
161. Sun X.J., Charbonneau C., Wei L., Yang W.T., Chen Q., Terek R.M. CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis. Mol. Cancer Ther. 2013, 12:1163-1170.
162. Sehgal A., Keener C., Boynton A.L., Warrick J., Murphy G.P. CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J. Surg. Oncol. 1998, 69:99-104.
163. Gao Z.J., Wang X.P., Wu K., Zhao Y., Hu G.Y. Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 Axis. Pancreatology 2010, 10:186-193.
164. Scotton C.J., Wilson J.L., Scott K., Stamp G., Wilbanks G.D., Fricker S., Bridger G., Balkwill F.R. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002, 62:5930-5938.
165. Singh S., Srivastava S.K., Bhardwaj A., Owen L.B., Singh A.P. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br. J. Cancer 2010, 103:1671-1679.
166. Rhodes L.V., Short S.P., Neel N.F., Salvo V.A., Zhu Y., Elliott S., Wei Y.K., Yu D.H., Sun M.H., Muir S.E., Fonseca J.P., Bratton M.R., Segar C., Tilghman S.L., Sobolik-Delmaire T., Horton L.W., Zaja-Milatovic S., Collins-Burow B.M., Wadsworth S., Beckman B.S., Wood C.E., Fuqua S.A., Nephew K.P., Dent P., Worthylake R.A., Curiel T.J., Hung M.C., Richmond A., Burow M.E. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011, 71:603-613.
167. Margolin D.A., Silinsky J., Grimes C., Spencer N., Aycock M., Green H., Cordova J., Davis N.K., Driscoll T., Li L. Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1alpha/CXCR4 paracrine signaling. Neoplasia 2011, 13:874-886.
168. Hartmann T.N., Burger J.A., Glodek A., Fujii N., Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005, 24:4462-4471.
169. Hattermann K., Mentlein R., Held-Feindt J. CXCL12 mediates apoptosis resistance in rat C6 glioma cells. Oncol. Rep. 2012, 27:1348-1352.
170. Dai X., Mao Z., Huang J., Xie S., Zhang H. The CXCL12/CXCR4 autocrine loop increases the metastatic potential of non-small cell lung cancer in vitro. Oncol. Lett. 2013, 5:277-282.
171. Mo W., Chen J., Patel A., Zhang L., Chau V., Li Y., Cho W., Lim K., Xu J., Lazar A.J., Creighton C.J., Bolshakov S., McKay R.M., Lev D., Le L.Q., Parada L.F. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell 2013, 152:1077-1090.
172. Huang M.Z., Li Y.Q., Zhang H.L., Nan F.F. Breast cancer stromal fibroblasts promote the generation of CD44(+)CD24(-) cells through SDF-1/CXCR4 interaction. J. Exp. Clin. Cancer Res. 2010, 29:80.
173. Dubrovska A., Hartung A., Bouchez L.C., Walker J.R., Reddy V.A., Cho C.Y., Schultz P.G. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br. J. Cancer 2012, 107:43-52.
174. Rhodes L.V., Bratton M.R., Zhu Y., Tilghman S.L., Muir S.E., Salvo V.A., Tate C.R., Elliott S., Nephew K.P., Collins-Burow B.M., Burow M.E. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-alpha)-positive breast cancer cells. Exp. Cell Res. 2011, 317:2573-2581.
175. Boimel P.J., Smirnova T., Zhou Z.N., Wyckoff J., Park H., Coniglio S.J., Qian B.Z., Stanley E.R., Cox D., Pollard J.W., Muller W.J., Condeelis J., Segall J.E. Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res. 2012, 14:R23.
176. Sun X., Cheng G., Hao M., Zheng J., Zhou X., Zhang J., Taichman R.S., Pienta K.J., Wang J. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010, 29:709-722.
177. Thelen M., Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio?. J. Neuroimmunol. 2008, 198:9-13.
178. Hernandez L., Magalhaes M.A.O., Coniglio S.J., Condeelis J.S., Segall J.E. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res. 2011, 13:R128.
179. Luker K.E., Lewin S.A., Mihalko L.A., Schmidt B.T., Winkler J.S., Coggins N.L., Thomas D.G., Luker G.D. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012, 31:4750-4758.
180. Miao Z., Luker K.E., Summers B.C., Berahovich R., Bhojani M.S., Rehemtulla A., Kleer C.G., Essner J.J., Nasevicius A., Luker G.D., Howard M.C., Schall T.J. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. USA 2007, 104:15735-15740.
181. Graham G.J., Locati M., Mantovani A., Rot A., Thelen M. The biochemistry and biology of the atypical chemokine receptors. Immunol. Lett. 2012, 145:30-38.
182. Smith M.C., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., Luker G.D. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004, 64:8604-8612.
183. Liang Z., Wu T., Lou H., Yu X., Taichman R.S., Lau S.K., Nie S., Umbreit J., Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 2004, 64:4302-4308.
184. Sun Y.X., Schneider A., Jung Y., Wang J., Dai J., Cook K., Osman N.I., Koh-Paige A.J., Shim H., Pienta K.J., Keller E.T., McCauley L.K., Taichman R.S. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J. Bone Miner. Res. 2005, 20:318-329.
185. Mori T., Doi R., Koizumi M., Toyoda E., Ito D., Kami K., Masui T., Fujimoto K., Tamamura H., Hiramatsu K., Fujii N., Imamura M. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol. Cancer Ther. 2004, 3:29-37.
186. Hiller D., Chu Q.D. CXCR4 and axillary lymph nodes: review of a potential biomarker for breast cancer metastasis. Int. J. Breast Cancer 2011, 2011:420981.
187. Li Y.M., Pan Y., Wei Y.K., Cheng X.Y., Zhou B.H.P., Tan M., Zhou X.Y., Xia W.Y., Hortobagyi G.N., Yu D.H., Hung M.C. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004, 6:459-469.
188. Kang H., Watkins G., Parr C., Douglas-Jones A., Mansel R.E., Jiang W.G. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res. 2005, 7:R402-R410.
189. White G.E., Iqbal A.J., Greaves D.R. CC chemokine receptors and chronic inflammation-therapeutic opportunities and pharmacological challenges. Pharmacol. Rev. 2013, 65:47-89.
190. Allegretti M., Cesta M.C., Garin A., Proudfoot A.E. Current status of chemokine receptor inhibitors in development. Immunol. Lett. 2012, 145:68-78.
191. Maeda K., Das D., Nakata H., Mitsuya H. CCR5 inhibitors: emergence, success, and challenges. Expert Opin. Emerg. Drugs 2012, 17:135-145.
192. Oishi S., Fujii N. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4). Org. Biomol. Chem. 2012, 10:5720-5731.
193. Peled A., Wald O., Burger J. Development of novel CXCR4-based therapeutics. Expert Opin. Investig. Drugs 2012, 21:341-353.
194. Ochoa-Callejero L., Perez-Martinez L., Rubio-Mediavilla S., Oteo J.A., Martinez A., Blanco J.R. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS ONE 2013, 8:e53992.
195. Swamydas M., Ricci K., Rego S.L., Dreau D. Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adhes. Migr. 2013, 7:315-324.
196. Sutton A., Friand V., Papy-Garcia D., Dagouassat M., Martin L., Vassy R., Haddad O., Sainte-Catherine O., Kraemer M., Saffar L., Perret G.Y., Courty J., Gattegno L., Charnaux N. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol. Cancer Ther. 2007, 6:2948-2958.
197. Kajiyama H., Shibata K., Terauchi M., Ino K., Nawa A., Kikkawa F. Involvement of SDF-1 alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int. J. Cancer 2008, 122:91-99.
198. D'Alterio C., Barbieri A., Portella L., Palma G., Polimeno M., Riccio A., Ierano C., Franco R., Scognamiglio G., Bryce J., Luciano A., Rea D., Arra C., Scala S. Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol. Immun. 2012, 61:1713-1720.
199. Ling X.Y., Spaeth E., Chen Y., Shi Y.X., Zhang W.G., Schober W., Hail N., Konopleva M., Andreeff M. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS ONE 2013, 8:e58426.
200. Liang Z., Zhan W., Zhu A., Yoon Y., Lin S., Sasaki M., Klapproth J.M., Yang H., Grossniklaus H.E., Xu J., Rojas M., Voll R.J., Goodman M.M., Arrendale R.F., Liu J., Yun C.C., Snyder J.P., Liotta D.C., Shim H. Development of a unique small molecule modulator of CXCR4. PLoS ONE 2012, 7:e34038.
201. O'Boyle G., Swidenbank I., Marshall H., Barker C.E., Armstrong J., White S.A., Fricker S.P., Plummer R., Wright M., Lovat P.E. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. Br. J. Cancer 2013, 108:1634-1640.
202. Parameswaran R., Yu M., Lim M., Groffen J., Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 2011, 25:1314-1323.
203. Kuhne M.R., Mulvey T., Belanger B., Chen S., Pan C., Chong C.L., Cao F., Niekro W., Kempe T., Henning K.A., Cohen L.J., Korman A.J., Cardarelli P.M. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin. Cancer Res. 2013, 19:357-366.
204. Liang Z., Brooks J., Willard M., Liang K., Yoon Y., Kang S., Shim H. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem. Biophys. Res. Commun. 2007, 359:716-722.
205. Tamamura H., Hori A., Kanzaki N., Hiramatsu K., Mizumoto M., Nakashima H., Yamamoto N., Otaka A., Fujii N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003, 550:79-83.
206. Richert M.M., Vaidya K.S., Mills C.N., Wong D., Korz W., Hurst D.R., Welch D.R. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol. Rep. 2009, 21:761-767.
207. Porvasnik S., Sakamoto N., Kusmartsev S., Eruslanov E., Kim W.J., Cao W., Urbanek C., Wong D., Goodison S., Rosser C.J. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009, 69:1460-1469.
208. Chen X., Xiao W., Qu X., Zhou S. The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro. Cancer Invest. 2008, 26:718-724.
209. Ma L.X., Qiao H.Q., He C.J., Yang Q., Cheung C.H.A., Kanwar J.R., Sun X.Y. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer. Invest. New Drug 2012, 30:508-517.
210. Mellor P., Harvey J.R., Murphy K.J., Pye D., O'Boyle G., Lennard T.W.J., Kirby J.A., Ali S. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br. J. Cancer 2007, 97:761-768.
211. Hutchings C.J., Koglin M., Marshall F.H. Therapeutic antibodies directed at G protein-coupled receptors. MAbs 2010, 2:594-606.
212. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am. J. Clin. Oncol. 2010, 33:186-195.
213. Garrett C.R., Eng C. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin. Biol. Ther. 2011, 11:937-949.
214. Baba M., Takashima K., Miyake H., Kanzaki N., Teshima K., Wang X., Shiraishi M., Iizawa Y. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. 2005, 49:4584-4591.
215. Nichols W.G., Steel H.M., Bonny T., Adkison K., Curtis L., Millard J., Kabeya K., Clumeck N. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob. Agents Chemother. 2008, 52:858-865.
216. Saita Y., Kondo M., Shimizu Y. Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int. Immunopharmacol. 2007, 7:1528-1534.
217. Teixeira M.M., Wells T.N., Lukacs N.W., Proudfoot A.E., Kunkel S.L., Williams T.J., Hellewell P.G. Chemokine-induced eosinophil recruitment, evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J. Clin. Invest. 1997, 100:1657-1666.
218. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 2005, 333:328-335.
219. Cheng J.W.M. Fondaparinux: a new antithrombotic agent. Clin. Ther. 2002, 24:1757-1769.
220. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006, 25:409-416.
221. Ben-Baruch A. The tumor-promoting flow of cells into, within and out of the tumor site: regulation by the inflammatory Axis of TNFalpha and chemokines. Cancer Microenviron. 2012, 5:151-164.
222. Naumann U., Cameroni E., Pruenster M., Mahabaleshwar H., Raz E., Zerwes H.G., Rot A., Thelen M. CXCR7 functions as a Scavenger for CXCL12 and CXCL11. PLoS ONE 2010, 5:e9175.
223. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
224. Lalezari J., Gathe J., Brinson C., Thompson M., Cohen C., Dejesus E., Galindez J., Ernst J.A., Martin D.E., Palleja S.M. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J. Acquir. Immune Defic. Syndr. 2011, 57:118-125.
225. Princen K., Hatse S., Vermeire K., Aquaro S., De Clercq E., Gerlach L.O., Rosenkilde M., Schwartz T.W., Skerlj R., Bridger G., Schols D. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J. Virol. 2004, 78:12996-13006.
226. Levina V., Su Y., Nolen B., Liu X., Gordin Y., Lee M., Lokshin A., Gorelik E. Chemotherapeutic drugs and human tumor cells cytokine network. Int. J. Cancer 2008, 123:2031-2040.
227. Kato T., Fujita Y., Nakane K., Mizutani K., Terazawa R., Ehara H., Kanimoto Y., Kojima T., Nozawa Y., Deguchi T., Ito M. CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling. Cytokine 2013, 64:251-257.
228. Hong M., Puaux A.L., Huang C., Loumagne L., Tow C., Mackay C., Kato M., Prevost-Blondel A., Avril M.F., Nardin A., Abastado J.P. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011, 71:6997-7009.
229. Hatano K., Yamaguchi S., Nimura K., Murakami K., Nagahara A., Fujita K., Uemura M., Nakai Y., Tsuchiya M., Nakayama M., Nonomura N., Kaneda Y. Residual Prostate Cancer Cells after Docetaxel Therapy Increase the Tumorigenic Potential via Constitutive Signaling of CXCR4, ERK1/2 and c-Myc. Mol. Cancer Res. 2013, 11:1088-1100.
230. Arora S., Bhardwaj A., Singh S., Srivastava S.K., McClellan S., Nirodi C.S., Piazza G.A., Grizzle W.E., Owen L.B., Singh A.P. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor kappaB- and hypoxia-inducible factor 1alpha-mediated up-regulation of CXCR4. J. Biol. Chem. 2013, 288:21197-21207.
231. Sison E.A., McIntyre E., Magoon D., Brown P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol. Cancer Res. 2013, 11:1004-1016.
232. Murakami J., Li T.S., Ueda K., Tanaka T., Hamano K. Inhibition of accelerated tumor growth by blocking the recruitment of mobilized endothelial progenitor cells after chemotherapy. Int. J. Cancer 2009, 124:1685-1692.
233. Kirk P.S., Koreckij T., Nguyen H.M., Brown L.G., Snyder L.A., Vessella R.L., Corey E. Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone. Int. J. Mol. Sci. 2013, 14:10483-10496.
234. Sharma B., Nawandar D.M., Nannuru K.C., Varney M.L., Singh R.K. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis. Mol. Cancer Ther. 2013, 12:799-808.
235. Wilson C., Purcell C., Seaton A., Oladipo O., Maxwell P.J., O'Sullivan J.M., Wilson R.H., Johnston P.G., Waugh D.J. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J. Pharmacol. Exp. Ther. 2008, 327:746-759.
236. Maung R., Medders K.E., Sejbuk N.E., Desai M.K., Russo R., Kaul M. Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury. J. Neuroimmune. Pharmacol. 2012, 7:306-318.
237. Ansari-Lari M.A., Liu X.M., Metzker M.L., Rut A.R., Gibbs R.A. The extent of genetic variation in the CCR5 gene. Nat. Genet. 1997, 16:221-222.
238. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist, AIDS Alert, 22 (2007) 103.
239. Cashen A.F. Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. Drug Today 2009, 45:497-505.